Chord gets $16m to challenge Alexion with oral NMOSD drugSwiss biotech Chord Therapeutics has come out of stealth mode with a $16 million first-round financing that will Share XChord gets $16m to challenge Alexion with oral NMOSD drughttps://pharmaphorum.com/news/chord-gets-16m-to-challenge-alexion-with-oral-nmosd-drug/
British biotechs look to Switzerland for clues to post-Brexit successTheresa May yesterday signed the letter that will formally begin the UK’s departure from the European Union, starting Share XBritish biotechs look to Switzerland for clues to post-Brexit successhttps://pharmaphorum.com/transversal-categories/uk-and-europe/british-biotechs-look-switzerland-clues-post-brexit-success/
Anthill extends its presence in DACH regionAnthill, a digital communications agency focused on the life science industry, is expanding its services for local clients Share XAnthill extends its presence in DACH regionhttps://pharmaphorum.com/partner-content-digital/anthill-extends-its-presence-in-dach-region/
A history of NovartisNovartis is one of the world’s top pharmaceutical companies, and along with neighbours Roche, the mainstay of Switzerland’s Share XA history of Novartishttps://pharmaphorum.com/articles/a-history-of-novartis/
